Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6

Oncologist

Volumn 17, Issue 3, 2012, Pages 296-302

  Kaldate, Rajesh R ^a   Haregewoin, Abebe ^a   Grier, Charles E ^a   Hamilton, Stephanie A ^a   McLeod, Howard L ^b  

^a Utah   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

5 fluorouracil; Area under the curve; Colorectal cancer; FOLFOX6; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; ALGORITHM; AREA UNDER THE CURVE; AREA UNDER THE CURVE DOSE RELATION; ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DATA BASE; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOKINETIC DOSING ALGORITHM; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84859406331     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0357     Document Type: Article

References (24)

1. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-336.
2. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997;32:324-343.
3. Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem 1993;39: 2419-2430.
4. Lamya Alnaim. Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer. SRX Pharmacology, vol. 2010, Article ID 352491, 12 pages, 2010. doi:10.3814/2010/352491
5. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised. Clin Pharmacokinet 2006;45:567-592.
6. Gamelin E, Boisdron-Celle M, Guérin-Meyer V et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-1110.
7. Saam J, Critchfield GC, Hamilton SA et al. Body surface area-based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 2011;10:203-206.
8. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005;165:1267-1273.
9. Colleoni M, Li S, Gelber RD et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005;366: 1108-1110.
10. Sparreboom A. BSA-based dosing and alternative approaches. Clin Adv Hematol Oncol 2005;3: 448-450.
11. Boisdron-Celle M, Remaud G, Traore S et al. 5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-282.
12. Adjei AA, Reid JM, Diasio RB et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002;20:1683-1691.
13. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. Relationship between 5-fluorouracil (5FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77: 441-451.
14. Gamelin E, Boisdron-Celle M, Delva R et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-1478.
15. Thyss A, Milano G, Renée N et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986;16:64-66.
16. Jodrell DI, Stewart M, Aird R et al. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. Br J Cancer 2001;84:600-603.
17. Santini J, Milano G, Thyss A et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-290.
18. Seitz JF, Cano JP, Rigault JP et al. [Chemotherapy of extensive digestive cancers with 5-fluorouracil: Relation between the clinical response and plasma clearance of the drug]. Gastroenterol Clin Biol 1983;7:374-380. In French.
19. Ychou M, Duffour J, Kramar A et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: Results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 2003;52: 282-290.
20. Milano G, Etienne MC, Renée N et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994;12:1291-1295.
21. Fety R, Rolland F, Barberi-Heyob M et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998;4:2039-2045.
22. Gamelin E, Delva R, Jacob J et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2099-2105.
23. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal cancer or head and neck cancer-status of the art. Crit Rev Oncol Hematol 1999;30:71-79.
24. ClinicalTrials.gov. Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (PROFUSE). Available at http://www.clinicaltrials. gov/ct2/show/NCT01468623?term profuse&rank 1, accessed on December 1, 2011.